543 related articles for article (PubMed ID: 11872748)
1. NF-kappa B as a therapeutic target in multiple myeloma.
Hideshima T; Chauhan D; Richardson P; Mitsiades C; Mitsiades N; Hayashi T; Munshi N; Dang L; Castro A; Palombella V; Adams J; Anderson KC
J Biol Chem; 2002 May; 277(19):16639-47. PubMed ID: 11872748
[TBL] [Abstract][Full Text] [Related]
2. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
Hideshima T; Richardson P; Chauhan D; Palombella VJ; Elliott PJ; Adams J; Anderson KC
Cancer Res; 2001 Apr; 61(7):3071-6. PubMed ID: 11306489
[TBL] [Abstract][Full Text] [Related]
3. Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
Hideshima T; Chauhan D; Podar K; Schlossman RL; Richardson P; Anderson KC
Semin Oncol; 2001 Dec; 28(6):607-12. PubMed ID: 11740818
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
Hideshima T; Ikeda H; Chauhan D; Okawa Y; Raje N; Podar K; Mitsiades C; Munshi NC; Richardson PG; Carrasco RD; Anderson KC
Blood; 2009 Jul; 114(5):1046-52. PubMed ID: 19436050
[TBL] [Abstract][Full Text] [Related]
5. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.
Berenson JR; Ma HM; Vescio R
Semin Oncol; 2001 Dec; 28(6):626-33. PubMed ID: 11740821
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.
Salem K; Brown CO; Schibler J; Goel A
Exp Hematol; 2013 Feb; 41(2):209-18. PubMed ID: 23063726
[TBL] [Abstract][Full Text] [Related]
7. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
Ma MH; Yang HH; Parker K; Manyak S; Friedman JM; Altamirano C; Wu ZQ; Borad MJ; Frantzen M; Roussos E; Neeser J; Mikail A; Adams J; Sjak-Shie N; Vescio RA; Berenson JR
Clin Cancer Res; 2003 Mar; 9(3):1136-44. PubMed ID: 12631619
[TBL] [Abstract][Full Text] [Related]
8. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.
Hideshima T; Chauhan D; Schlossman R; Richardson P; Anderson KC
Oncogene; 2001 Jul; 20(33):4519-27. PubMed ID: 11494147
[TBL] [Abstract][Full Text] [Related]
9. Moving disease biology from the lab to the clinic.
Anderson KC
Cancer; 2003 Feb; 97(3 Suppl):796-801. PubMed ID: 12548578
[TBL] [Abstract][Full Text] [Related]
10. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.
Hideshima T; Chauhan D; Ishitsuka K; Yasui H; Raje N; Kumar S; Podar K; Mitsiades C; Hideshima H; Bonham L; Munshi NC; Richardson PG; Singer JW; Anderson KC
Oncogene; 2005 Apr; 24(19):3121-9. PubMed ID: 15735676
[TBL] [Abstract][Full Text] [Related]
12. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
13. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
Lam LT; Davis RE; Pierce J; Hepperle M; Xu Y; Hottelet M; Nong Y; Wen D; Adams J; Dang L; Staudt LM
Clin Cancer Res; 2005 Jan; 11(1):28-40. PubMed ID: 15671525
[TBL] [Abstract][Full Text] [Related]
14. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
Yasui H; Hideshima T; Ikeda H; Jin J; Ocio EM; Kiziltepe T; Okawa Y; Vallet S; Podar K; Ishitsuka K; Richardson PG; Pargellis C; Moss N; Raje N; Anderson KC
Br J Haematol; 2007 Feb; 136(3):414-23. PubMed ID: 17173546
[TBL] [Abstract][Full Text] [Related]
15. Long-term incubation with proteasome inhibitors (PIs) induces IκBα degradation via the lysosomal pathway in an IκB kinase (IKK)-dependent and IKK-independent manner.
Lee KH; Jeong J; Yoo CG
J Biol Chem; 2013 Nov; 288(45):32777-32786. PubMed ID: 24085292
[TBL] [Abstract][Full Text] [Related]
16. The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.
Dong QG; Sclabas GM; Fujioka S; Schmidt C; Peng B; Wu T; Tsao MS; Evans DB; Abbruzzese JL; McDonnell TJ; Chiao PJ
Oncogene; 2002 Sep; 21(42):6510-9. PubMed ID: 12226754
[TBL] [Abstract][Full Text] [Related]
17. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
Zheng B; Georgakis GV; Li Y; Bharti A; McConkey D; Aggarwal BB; Younes A
Clin Cancer Res; 2004 May; 10(9):3207-15. PubMed ID: 15131062
[TBL] [Abstract][Full Text] [Related]
18. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.
Du HF; Yu LJ; Meng YF; Lv HY; Meng J; Song XN; Zhang JQ
Leuk Lymphoma; 2013 Mar; 54(3):607-18. PubMed ID: 22889356
[TBL] [Abstract][Full Text] [Related]
19. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis.
Bharti AC; Donato N; Singh S; Aggarwal BB
Blood; 2003 Feb; 101(3):1053-62. PubMed ID: 12393461
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
Hideshima T; Chauhan D; Hayashi T; Podar K; Akiyama M; Mitsiades C; MItsiades N; Gong B; Bonham L; de Vries P; Munshi N; Richardson PG; Singer JW; Anderson KC
Cancer Res; 2003 Dec; 63(23):8428-36. PubMed ID: 14679006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
